The Influence of Chronic Liver Diseases on Hepatic Vasculature: A Liver-on-a-chip Review

Abstract

In chronic liver diseases and hepatocellular carcinoma, the cells and extracellular matrix of the liver undergo significant alteration in response to chronic injury. Recent literature has highlighted the critical, but less studied, role of the liver vasculature in the progression of chronic liver diseases. Recent advancements in liver-on-a-chip systems has allowed in depth investigation of the role that the hepatic vasculature plays both in response to, and progression of, chronic liver disease. In this review, we first introduce the structure, gradients, mechanical properties, and cellular composition of the liver and describe how these factors influence the vasculature. We summarize state-of-the-art vascularized liver-on-a-chip platforms for investigating biological models of chronic liver disease and their influence on the liver sinusoidal endothelial cells of the hepatic vasculature. We conclude with a discussion of how future developments in the field may affect the study of chronic liver diseases, and drug development and testing.

Tumor Microenvironment Alters Chemoresistance of Hepatocellular Carcinoma Through CYP3A4 Metabolic Activity

“…However, these studies did not investigate the regulation of cellular metabolism, including CYP3A4 activity, under different microenvironmental conditions ( 26 , 27 , 33 , 34 ). Recent work extending these efforts has demonstrated significant potential in utilizing collagen tunability to replicate native microenvironment properties (pH, stiffness, fiber properties, and porosity) ( 35 , 36 ), demonstrating promise in replicating physiological TME to investigate the modulation of CYP3A4 activity and chemoresistance.…”

Combining Chemistry and Engineering for Hepatocellular Carcinoma: Nano-Scale and Smaller Therapies

“…This shows that the formation of functional vasculature in 3D microfluidic platforms can be accomplished in several days under physiological flow conditions. These models enable us to study the dynamic determination of vessel permeability, the measurement of drug transport, and associated efficacy [ 85 , 89 ]. They also replicate the pharmacodynamics and pharmacokinetics of the human liver when designed according to allometric scaling laws [ 90 ].…”

Drug-induced Fatty Liver Disease: Pathogenesis and Treatment

“…In addition, there are numerous drugs which can cause progression of steatohepatitis. 26 In 2015, Satapathy et al 27 have shown that tamoxifen, an anti-estrogenic drug used in the treatment and prevention of breast cancer, was frequently associated with hepatic steatosis, although rarely with cirrhosis or steatohepatitis. Moreover, the authors emphasized that chronic exposure to amiodarone, 4, 4′-diethylaminoethoxyhexestrol and perhexiline maleate rarely led to cirrhosis.…”